Denis Villeneuve Is the Next Bond Director. So What Will His 007 Look Like?
Arrival. Blade Runner 2049. Dune. And now, Bond. Amazon MGM Studios just named Québécois auteur Denis Villeneuve the next James Bond movie. (Colloquially known as "Bond 26" until a real title comes along.) Now wielding the keys to the Aston Martin, Villeneuve's involvement raises big questions about the future for the spy franchise. Mainly: What's Bond 26 going to look like?
First, the basics. Not only will this mark Villeneuve's first time working on the series in any form, but also producers Amy Pascal and David Heyman—who took the reins from the Broccolis after they ceded control to Amazon last February. It will also be the series debut of whatever actor will play James Bond next, following Daniel Craig's retirement in 2021's No Time to Die. Truly, we're in a brave new world for Bond.
"I'm a die-hard Bond fan. To me, he's sacred territory," Villeneuve said in a statement, where he added that he shared the 007 movies with his father since Dr. No with Sean Connery. "I intend to honor the tradition and open the path for many new missions to come. This is a massive responsibility, but also, incredibly exciting for me and a huge honor."
Villeneuve is excited to take on Bond—who wouldn't be?!—but an auteur taking over a revered film series comes with plenty of questions and speculation that a lesser-known director wouldn't necessarily attract. Amazon MGM's choice is even more interesting when you factor Villeneuve's existing body of work, a number of which are expansive science fiction features that oscillate between refined and oppressive sensibilities.
Judging by what we've broadly seen across his eleven films (beginning with his filmmaking debut August 32nd on Earth, from 1998), we might get a more tech-sophisticated Bond. You know the scenes where Bond meets Q and gets a fancy gadget? It's screaming Denis Villeneuve. And whatever the plot might be, you can bet the villain will dwell in some elaborate lair—with lots of empty space, of course—in which they pontificate their plans with deep solemnity.
If Villeneuve leans toward a version of the Bond he grew up on, though, perhaps Bond 26 will be the opposite of what Blade Runner 2049 and the Dunes looked like. (Especially if Dune: Messiah, which begins filming this summer and comes out 2026, doesn't tucker him out from architectural straight lines and gunmetal-gray color palettes.) A Bond 26 that leans into funkier retro aesthetics, found in the Connery, Lazenby, and Moore eras—or the over-the-top bombast that defined Dalton and Brosnan—or something that's all of the above, seems plausible for Villeneuve.
Back in 2015, Villeneuve told ComingSoon that directing Bond would be a dream, and that it would be an invitation to try something different. "I understand that each genre has its own specific rules, but for me, they are all movies," he said. "I'm just attracted to try to do different things, and I was very excited to make a movie that required more action. I was raised with James Bond. I love James Bond movies. I would love to do a James Bond movie one day. Action is very cinematic. I'm not someone that loves dialogue—I am someone that loves movement. Action, if it's well done, can be very poetic and meaningful."
In a 2021 appearance on the podcast Happy Sad Confused, Villeneuve called Bond "a dream to do" and "pure cinematic joy." Whether Villeneuve's definition of joy means remaking Moonraker or making Bond even more of an iconoclast in a rapidly evolving world is yet to be seen. But the Villeneuve era of Bond is already shaping up to be the biggest paradigm shift since Craig stood up on a sandbar in Casino Royale.
Basically: Get ready for Bond to get shaken, not stirred.
You Might Also Like
Kid Cudi Is All Right
16 Best Shoe Organizers For Storing and Displaying Your Kicks
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
an hour ago
- CNN
‘I wanted to do something to fight back': Developer makes app to flag ICE raids
Joshua Aaron, a musician and developer, created an app called ICEBlock, where people can post sightings of U.S. Immigration and Customs Enforcement officers across the country. CNN's Clare Duffy speaks to Aaron about what motivated him to create the application and the efforts he has made to keep it accurate and prevent it from identifying users.
Associated Press
2 hours ago
- Associated Press
Texas Legislature Passes IonQ-Supported Quantum Initiative, Advancing Quantum Ecosystem Across the State
COLLEGE PARK, Md.--(BUSINESS WIRE)--Jun 30, 2025-- IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced its commitment to helping build a thriving quantum ecosystem in Texas, following the passage of the Texas Quantum Initiative (HB 4751) in the 89th Texas Legislature. This legislation positions Texas to become a major hub for quantum innovation. IonQ's engagement with Texas policymakers and research institutions reflects its broader vision to expand regional quantum economies across the United States. Earlier this year, IonQ CEO Niccolo de Masi testified before the Texas Senate Business and Commerce Committee in support of HB 4751, emphasizing the critical role of quantum computing in addressing future cybersecurity and economic challenges. 'The Texas Quantum Initiative is more than just policy. It's a platform for transformative innovation, secure infrastructure, and inclusive workforce development,' said Niccolo de Masi, CEO of IonQ. 'We commend Governor Abbott, Chairman Capriglione, Senator Parker, Chairman Schwertner and the Texas legislature, for taking bold steps to secure Texas's place in the global quantum economy. IonQ is excited to collaborate with Texas leaders, universities, and industry to help catalyze a new era of quantum-powered solutions.' The Texas Quantum Initiative establishes a strategic framework to leverage the state's academic strength, technology sector, and entrepreneurial drive. It will provide guidance, investment incentives, and research opportunities that advance quantum computing, networking, and sensing technologies. 'Quantum technology is no longer a distant idea; it is quickly becoming a reality, influencing national security, manufacturing, pharmaceuticals, climate science, and critical infrastructure,' said Chairman Capriglione. 'The U.S. and other nations are competing to develop and implement these capabilities. The Texas Quantum Initiative helps Texas lead in this field by encouraging quantum innovation and fast-tracking the integration of quantum tech into the state's economy.' IonQ's participation in SXSW 2025 quantum events – alongside Texas lawmakers and industry peers – further underscored the company's readiness to contribute to Texas's quantum momentum. In addition to its ongoing collaboration with academic and industry partners nationwide, IonQ will look to support education and training programs in Texas. 'Quantum technologies offer unparalleled potential to protect digital infrastructure, optimize systems, and uncover solutions that were once beyond reach,' de Masi added. 'We believe Texas is poised to play a defining role in the future of this technology.' About IonQ IonQ, Inc. is a leading commercial quantum computing and networking company, delivering high-performance systems aimed at solving the world's largest and most complex commercial and research use cases. IonQ's current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems and represent the forefront of the company's technological roadmap as it advances toward its goal of building quantum computers with 2 million physical qubits by 2030. The company's innovative technology and rapid growth were recognized in Newsweek's 2025 Excellence Index 1000, Forbes' 2025 Most Successful Mid-Cap Companies list, and Built In's 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words 'advances,' 'aimed,' 'available,' 'believe,' 'build,' 'catalyze,' 'collaborate,' 'commitment,' 'contribute,' 'cutting-edge,' 'delivering,' 'forefront,' 'goal,' 'impactful,' 'ongoing,' 'potential,' 'will,' and other similar expressions are intended to identify forward-looking statements. These statements include those related to the IonQ's quantum computing capabilities and plans; IonQ's technology driving commercial quantum advantage; the future impacts of IonQ's offerings available today; and the scalability, fidelity, efficiency, viability, accessibility, effectiveness, importance, reliability, performance, speed, impact, practicality, feasibility, and commercial-readiness of IonQ's offerings. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ's ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ's ability to deliver, and customers' ability to generate, value from IonQ's offerings; IonQ's ability to sell effectively to government organizations and large enterprises; IonQ's ability to implement its business plans, forecasts, roadmaps and other expectations, to identify and realize partnerships and opportunities, and to engage new and existing customers; IonQ's ability to effectively enter new markets; IonQ's ability to deliver services and products within currently anticipated timelines; IonQ's customers deciding or declining to extend contracts into new phases; changes in U.S. government spending or policy that may affect IonQ's customers; and risks associated with U.S. government sales, including availability of funding and provisions that may allow the government to unilaterally terminate or modify contracts for convenience. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company's filings, including but not limited to those described in the 'Risk Factors' section of IonQ's filings with the U.S. Securities and Exchange Commission, including but not limited to the Company's most recent Annual Report on Form 10-K and reports on Form 10-Q. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future. View source version on CONTACT: IonQ Media contact: Jane Mazur [email protected] Investor Contact: [email protected] KEYWORD: UNITED STATES NORTH AMERICA TEXAS MARYLAND INDUSTRY KEYWORD: SOFTWARE RESEARCH NETWORKS OTHER DEFENSE INTERNET CONTRACTS HARDWARE TECHNOLOGY DEFENSE SEMICONDUCTOR SCIENCE OTHER SCIENCE SOURCE: IonQ Copyright Business Wire 2025. PUB: 06/30/2025 07:05 AM/DISC: 06/30/2025 07:05 AM
Forbes
2 hours ago
- Forbes
How AI In Medical Writing Will Save Money And Accelerate Drug Delivery
The tightly regulated life sciences sector needs specialisy AI solutions for content produciton Generative artificial intelligence (GenAI) promises to transform the life sciences sector. But while excitement is understandably mounting about the potential to use the technology to develop new drugs and save lives, other uses of AI in the sector are often overlooked. That's despite the huge value on offer here. A recent study from the consultant McKinsey found that leaving aside clinical and R&D use cases for GenAI in the life sciences sector, the technology has the potential to produce more than $50 billion of value each year across the pharmaceutical industry value chain. Medical writing is one significant part of that opportunity. The highly-regulated process of creating literature for regulators, healthcare professionals, patients and other key stakeholders is hugely costly for life sciences business. Research from Deloitte suggests that automating more of this process could reduce the workload of a medical writer by up to 30%, driving cost savings of up to $30 million a year for a large life sciences company. A survey published last year by the Regulatory Affairs Professionals Society found 57% of companies planned to invest in technology to support their medical writing workflows. There's also the potential to speed up the process of bringing new treatments to market, since getting regulatory approval for new drugs often depends on multiple submissions and reports. 'One immediate area of opportunity for streamlining clinical trials is clinical and regulatory medical writing,' concluded the American Medical Writers Association in a recent paper. 'GenAI has the potential to revolutionize medical writing by automating routine tasks, improving consistency and quality, and enabling faster turnaround times.' Established life sciences industry players such as Parexel, Syneos Health and Trilogy are increasingly developing solutions that meet this need, but the sector is also home to a number of innovative new entrants. LogicFlo AI is one such start-u. The Boston-based company is today announcing it has raised $2.7 million of seed funding from investors in order to scale its agentic AI business. The contention of co-founders Udith Vaidyanathan and Arun Ramakrishnan is that while AI can help life sciences businesses produce vital content and documentation more efficiently and cost-effectively, the highly specialised and regulated nature of the industry means it needs solutions that have been designed expressly for this purpose. 'The cost of an inaccuracy or omission in life sciences is potentially huge,' argues Vaidyanathan. 'Generic AI tools aren't reliable enough for these tasks and processes, and it's also critical that every claim made in documentation is sourced so that it can be checked and verified.' LogicFlo's approach has therefore been to develop a set of AI agents that can interact with life science companies' existing technologies – systems such as Veeva and IQVIA – in order to automate the creation of the content they need. Every piece of literature produced can then be checked by a human being, but staff no longer need to spend countless hours developing the documents from scratch in the first place. 'The life sciences industry is employing thousands of highly-qualified professionals who then have to spend huge amounts of their time on medical writing,' says Vaidyanathan, who saw this problem first-hand in his previous role supporting the CEO office at the global life sciences business Abbott. 'If we can reduce that burden, we can free them up to do much more of the work they're qualified for.' LogicFlo founders Udith Vaidyanathan and Arun Ramakrishna It's a proposition that has already seen LogicFlo, founded last year, win a number of commercial customers, including a Fortune 500 life sciences business with around 10,000 professionals in functions such as medical affairs, quality, regulation and promotional content. 'Traditional automation has failed life sciences because it's too rigid, too brittle and too out of touch with how people actually work,' adds Ramakrishnan In practice, LogicFlo's technology can be used for a range of tasks where the stakes are particularly high, including medical literature writing, medical communications and information response, regulatory submissions and responses, and the production of a range of promotional and marketing materials. In each case, life sciences businesses are held to much higher standards than their counterparts in non-regulated industries and therefore need specialist tools to produce accurate and detailed material that stands up to close scrutiny. It's this differentiation that has attracted investors to LogicFlo, which plans to use its funding for recruitment and engineering. The round was led by Lightspeed with participation from a number of business angels from across the healthcare and life sciences sector. 'LogicFlo's AI agent platform empowers medical affairs and commercial teams to build agentic workflows across diverse use cases, dramatically boosting productivity,' says Rohil Bagga, VP of investments at Lightspeed. There's certainly plenty of market to go at. The market for AI In medical writing was worth $685 million last year, according to Credence Research, but will grow to $1.58 billion by 2032, it estimates. That's growth of around 11% a year – likely enticing enough to attract more new entrants to the sector in the coming months and years.
